KI-1 LARGE-CELL LYMPHOMA - A CLINICAL-STUDY OF 12 CASES

The treatment and prognosis of Ki-1 positive lymphoma, a relatively ne w entity, remains largely unknown and the clinical features are still being defined. This is a retrospective analysis of our experience with 12 patients with Ki-1 lymphoma who were treated at our hospital over two years. Clinical presentation and management are described and an a ttempt is made to identify prognostic factors. The median age at prese ntation was 20 and the male/female ratio 1:1. Nine patients presented with nodal disease and three with extranodal. B symptoms were present in seven patients. Seven patients had stage I/II disease and five had stage IV. Immunophenotyping was available in 10 patients of which five were T-cell, two B-cell, and two null cell; one could not be categori zed. All 12 patients received combination chemotherapy; five had conso lidation radiotherapy. With a median follow-up of 11 months (range one to 29), actuarial survival was 67% at 29 months and disease-free surv ival 50% for all patients. Five out of seven patients with stage I/II and one out of five with stage IV remain disease free. We conclude tha t the clinical presentation is diverse and advanced stage appears to b e the only identifiable adverse prognostic factor.